Study Evaluating Piperacillin-Tazobactam on Certain Bacteria in Hematology and Oncology Units
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00167999 |
Recruitment Status
:
Completed
First Posted
: September 14, 2005
Last Update Posted
: March 15, 2007
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Gram-Positive Bacterial Infections Escherichia Coli Infections Klebsiella Infections | Drug: piperacillin-tazobactam |
Study Type : | Observational |
Enrollment : | 200 participants |
Observational Model: | Case Control |
Observational Model: | Natural History |
Time Perspective: | Longitudinal |
Time Perspective: | Prospective |
Official Title: | Effects of Piperacillin-Tazobactam Use on the Prevalence Rate of Extended-Spectrum Beta-Lactamase (ESBL) Producing Escherichia Coli and Klebsiella Pneumoniae in Hematology and Oncology Units. |
Study Start Date : | February 2005 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 15 Years and older (Child, Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Eligible patients of either sex, 15 years of age or older
- Patients who are admitted to the department of hematology and oncology
- Provide written informed consent
Exclusion Criteria:
- Patients who have hypersensitivity to β-lactam antibiotics
- Female who are pregnant or breast-feeding
- Any underlying conditions or non-infectious diseases that will be ultimately fatal within 30 days

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00167999
Korea, Republic of | |
Seoul, Korea, Republic of, 133-792 |
Study Director: | Medical Monitor | Wyeth is now a wholly owned subsidiary of Pfizer |
ClinicalTrials.gov Identifier: | NCT00167999 History of Changes |
Other Study ID Numbers: |
0910X-101676 |
First Posted: | September 14, 2005 Key Record Dates |
Last Update Posted: | March 15, 2007 |
Last Verified: | March 2007 |
Keywords provided by Wyeth is now a wholly owned subsidiary of Pfizer:
Bacterial Infections |
Additional relevant MeSH terms:
Infection Communicable Diseases Bacterial Infections Klebsiella Infections Gram-Positive Bacterial Infections Escherichia coli Infections Enterobacteriaceae Infections Gram-Negative Bacterial Infections Tazobactam |
Penicillanic Acid Piperacillin Piperacillin, tazobactam drug combination Anti-Bacterial Agents Anti-Infective Agents beta-Lactamase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |